WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules

Firma WELDINGAllgemein, , , , , , , , , , , , , ,

WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in collaboration with its partner Zenara Pharma Pvt Ltd has received its Mehr

WELDING GmbH & Co. KG Expands to Latin America

Firma WELDINGFirmenintern, , , , , , , , , , , , , ,

WELDING GmbH & Co. KG announces the establishment of its Mexican subsidiary, WELDING Ingredientes SA de CV. With this step, our family-owned company is expanding its international presence and strengthening its position in the Latin American market. Our goal is Mehr

Revio Therapeutics and Welding Group Announce Strategic Co-Development and Licensing Agreement for Innovative Specialty Oncology Product

Firma WELDINGAllgemein, , , , , , , , , , ,

Revio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form with significant patient compliance and ease-of-use advantages, will be developed Mehr